Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07762573
Recruiting Observational

Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective Study

NCT07762573 · tracked via the Priya Life Science China tracker
Sponsor
Nanfang Hospital, Southern Medical University
Phase
Observational
Started
2026-08-03
Last updated
2026-08-13

Condition(s) studied

Chronic Obstructive Pulmonary Disease

Study summary

To evaluate the utility of DCR-derived parameters for identifying dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of disease progression in COPD.

Eligibility

Sex
ALL
Min age
30 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: 1. Aged 30-85 years. 2. Male or female. 3. Patients who underwent pulmonary function testing and dynamic chest radiography at the hospital. Exclusion Criteria: 1. Incomplete medical records. 2. Considered unsuitable for inclusion in the study at the investigator's discretion.

Primary outcome measure(s)

  • Exacerbation/respiratory history and event — At Baseline
    Measurement of disease control and burden
  • FEV1 % — At Baseline
    Measurement of lung function
  • FEV1 /FVC — At Baseline
    Measurement of lung function
  • Emphysema — At Baseline
    Measurement of chest CT
  • diaphragm movement — At Baseline
    Measurement of Dynamic chest radiograph
  • lung field area — At Baseline
    Measurement of Dynamic chest radiograph
  • lung field area change rate — At Baseline
    Measurement of Dynamic chest radiograph
  • CAT — At Baseline
    Measurement of questionnaires
  • SGRQ — At Baseline
    Measurement of questionnaires
  • mMRC — At Baseline
    Measurement of questionnaires
  • Smoking history and status — At Baseline
    Risk factors of COPD development or lung function decline

Trial sites (1)

FacilityCityRegionStatus
Nanfang Hospital, Southern Medical University Guangzhou Guangdong Recruiting

More Nanfang Hospital, Southern Medical University trials in China

Immune Dynamics in the Natural History of Chronic HBV Infection Recruiting
Anterior Segment Anatomy Assessed by Swept-Source OCT in Ocular Surgery Patients Recruiting
Correlation and Predictive Research of Metal Elements in Radiation-Induced Oral Mucositis Recruiting
Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy Starting soon
Large Language Model-Based Emotional Management for Breast Cancer Patients Active, not recruiting

Other trials for the same condition

Safety and Efficacy of Endobronchial Valve for Bronchoscopic Lung Volume Reduction Surgery: a Prospective Pilot Study Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Active, not recruiting
The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations Active, not recruiting
A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease Recruiting
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07762573 on ClinicalTrials.gov ↗ ← All trials in China